Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sharon Bio-Medicine has informed that the resolution professional on 22 February 2018 has approved and considered the standalone unaudited Financial results of the company with the Limited review report for the quarter and nine months ended December 31, 2017.
The above information is a part of company’s filings submitted to BSE.